GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » EV-to-EBIT

Cereno Scientific AB (OSTO:CRNO B) EV-to-EBIT : -34.64 (As of Jul. 10, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cereno Scientific AB's Enterprise Value is kr2,676.75 Mil. Cereno Scientific AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-77.26 Mil. Therefore, Cereno Scientific AB's EV-to-EBIT for today is -34.64.

The historical rank and industry rank for Cereno Scientific AB's EV-to-EBIT or its related term are showing as below:

OSTO:CRNO B' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.14   Med: 0   Max: 0
Current: -34.64

OSTO:CRNO B's EV-to-EBIT is ranked worse than
100% of 684 companies
in the Drug Manufacturers industry
Industry Median: 17.605 vs OSTO:CRNO B: -34.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cereno Scientific AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr1,685.16 Mil. Cereno Scientific AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-77.26 Mil. Cereno Scientific AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -4.58%.


Cereno Scientific AB EV-to-EBIT Historical Data

The historical data trend for Cereno Scientific AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB EV-to-EBIT Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.69 -30.01 -8.14 -24.01 -21.95

Cereno Scientific AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.48 -21.24 -36.46 -21.95 -21.81

Competitive Comparison of Cereno Scientific AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's EV-to-EBIT falls into.


;
;

Cereno Scientific AB EV-to-EBIT Calculation

Cereno Scientific AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2676.746/-77.263
=-34.64

Cereno Scientific AB's current Enterprise Value is kr2,676.75 Mil.
Cereno Scientific AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-77.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cereno Scientific AB  (OSTO:CRNO B) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cereno Scientific AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-77.263/1685.15673
=-4.58 %

Cereno Scientific AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr1,685.16 Mil.
Cereno Scientific AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-77.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cereno Scientific AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines